Singapore markets closed

Straits Times Index
3,280.10
-7.65(-0.23%)
Nikkei
37,934.76
+306.28(+0.81%)
Hang Seng
17,651.15
+366.61(+2.12%)
FTSE 100
8,139.83
+60.97(+0.75%)
Bitcoin USD
63,554.84
+571.98(+0.91%)
CMC Crypto 200
1,389.29
-7.25(-0.52%)

Hikma Pharmaceuticals PLC (HKMPF)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

22.33

0.00

(0.00%)

At close: 09:49AM EDT

Loading interactive chart…

Simply Wall St.
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
Simply Wall St.
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Reuters
Merck's Bridion faces generic threat from drugmaker Hikma
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.